Zosano Pharma Corp
F:0ZPN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Zosano Pharma Corp
Change in Working Capital
Zosano Pharma Corp
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Z
|
Zosano Pharma Corp
F:0ZPN
|
Change in Working Capital
-$2.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Change in Working Capital
-$246m
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Change in Working Capital
$154.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Stryker Corp
NYSE:SYK
|
Change in Working Capital
-$373m
|
CAGR 3-Years
33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Change in Working Capital
-$803m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
6%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Change in Working Capital
-$1.3B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-30%
|
|
Zosano Pharma Corp
Glance View
Zosano Pharma Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Fremont, California and currently employs 40 full-time employees. The company went IPO on 2015-01-27. Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The firm is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using its transdermal microneedle system (the System). Its System is designed to facilitate rapid drug absorption into the bloodstream, and to provide an improved pharmacokinetic (PK) profile compared to original dosage forms. The System consists of a three cm square to six cm square array of titanium microneedles approximately 200-350 microns in length, coated with a hydrophilic formulation of drug, mounted on an adhesive patch. The company is focused on development of its lead product candidate, M207, a formulation of zolmitriptan, which is used as an acute treatment for migraine. Its zolmitriptan formulation is delivered utilizing its system. M207 is designed to provide rapid absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract.
See Also
What is Zosano Pharma Corp's Change in Working Capital?
Change in Working Capital
-2.8m
USD
Based on the financial report for Mar 31, 2022, Zosano Pharma Corp's Change in Working Capital amounts to -2.8m USD.
What is Zosano Pharma Corp's Change in Working Capital growth rate?
Change in Working Capital CAGR 1Y
-13%
Over the last year, the Change in Working Capital growth was -13%.